东京肝癌化疗研究组开展的依托泊苷治疗肝细胞癌患者的II期研究。
A phase II study of etoposide in patients with hepatocellular carcinoma by the Tokyo Liver Cancer Chemotherapy Study Group.
作者信息
Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, Hashimoto N
机构信息
Department of Internal Medicine, National Cancer Center Hospital, Tokyo.
出版信息
Jpn J Clin Oncol. 1989 Jun;19(2):120-2.
Twenty-four patients with hepatocellular carcinoma were treated with 80 mg etoposide/m2 for five consecutive days at 4-week intervals. Of the 21 patients evaluated, only one showed a partial response (of 8 weeks, duration). The dose-limiting factor was bone marrow suppression. Grades 3 and 4 white blood cell count toxicity occurred in five (24%) and two (10%) patients, respectively. Alopecia (grades 1 and 2) was observed in 18 patients (57%). The The present study indicates that etoposide has very limited activity against hepatocellular carcinoma.
24例肝细胞癌患者接受依托泊苷治疗，剂量为80mg/m²，连续5天给药，每4周为一个周期。在评估的21例患者中，仅有1例出现部分缓解（持续时间为8周）。剂量限制因素为骨髓抑制。3级和4级白细胞计数毒性分别发生在5例（24%）和2例（10%）患者中。18例患者（57%）出现脱发（1级和2级）。本研究表明，依托泊苷对肝细胞癌的活性非常有限。
Zotero 插件